Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $11 at SunTrust
August 8, 2019 1:03 PM EDTSunTrust analyst Edward Nash raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $11.00 (from $9.00) while maintaining a Buy rating.
weakness a buying opportunity ahead of MuSK-MG topline in 1st-half of 2020... More
Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 9c
August 7, 2019 5:18 PM EDTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.11, $0.09 better than the analyst estimate of $0.02. Revenue for the quarter came in at $28.8 million versus the consensus estimate of $18.49 million.
We are very pleased with the continued strength of the commercial launch of Firdapse®, the... More
